Figure 1.
(A, B) Progression-free survival (PFS) and overall survival (OS) for all patients (A, B). (C and D) Comparison of progression-free survival (PFS) (C) and overall survival (OS) (D) between VIPD group and L/P-VIPD group for early stage ENKTL patients. (E and F) Impact of pretreatment SUVmax on the PFS (E) and OS (F) for ENKTL patients. (G and H) Significant impact of PINK on progression-free survival (PFS) (E) and overall survival (OS).